The Pathophysiology of Epithelial-Mesenchymal Transition Induced by Transforming Growth Factor-β in Normal and Malignant Mammary Epithelial Cells
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Epithelial-mesenchymal transition (EMT) is an essential process that drives polarized, immotile mammary epithelial cells (MECs) to acquire apolar, highly migratory fibroblastoid-like features. EMT is an indispensable process that is associated with normal tissue development and organogenesis, as well as with tissue remodeling and wound healing. In stark contrast, inappropriate reactivation of EMT readily contributes to the development of a variety of human pathologies, particularly those associated with tissue fibrosis and cancer cell invasion and metastasis, including that by breast cancer cells. Although metastasis is unequivocally the most lethal aspect of breast cancer and the most prominent feature associated with disease recurrence, the molecular mechanisms whereby EMT mediates the initiation and resolution of breast cancer metastasis remains poorly understood. Transforming growth factor-β (TGF-β) is a multifunctional cytokine that is intimately involved in regulating numerous physiological processes, including cellular differentiation, homeostasis, and EMT. In addition, TGF-β also functions as a powerful tumor suppressor in MECs, whose neoplastic development ultimately converts TGF-β into an oncogenic cytokine in aggressive late-stage mammary tumors. Recent findings have implicated the process of EMT in mediating the functional conversion of TGF-β during breast cancer progression, suggesting that the chemotherapeutic targeting of EMT induced by TGF-β may offer new inroads in ameliorating metastatic disease in breast cancer patients. Here we review the molecular, cellular, and microenvironmental factors that contribute to the pathophysiological activities of TGF-β during its regulation of EMT in normal and malignant MECs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196 · cited 5×
“The initiation of type 3 EMT is essential in facilitating cancer progression and metastasis, including that by mammary tumors [1, 2].”
InfluentialEpithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
Molecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108 · cited 3×
“differentiation, invasion, and EMT [243].”
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121
TGF-β-induced epithelial to mesenchymal transition
Xu, J., Lamouille, S., & Derynck, R. (2009) · Cell Research · doi:10.1038/cr.2009.5 · Cited by 2,804 · cited 3×
“Oncogenic TGF-β signaling is often associated with the dysregulated activity of the Rho GTPase family, which includes RhoA/B/C, Rac1, and Cdc42 [1, 14, 20].”
Ignotz, R. A., & Massagué, J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35666-1 · Cited by 2,492
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445 · cited 1×
“advantages to developing carcinomas [145].”
Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272 · cited 1×
“highly motile counterparts that express vimentin [215].”
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Generation of a functional mammary gland from a single stem cell
Shackleton, M., Vaillant, F., Simpson, K. J., Stingl, J., Smyth, G. K., Asselin-Labat, M.-L., Wu, L., Lindeman, G. J., & Visvader, J. E. (2006) · Nature · doi:10.1038/nature04372 · Cited by 2,005
Yu, Q., & Stamenkovic, I. (2000) · Genes & Development · doi:10.1101/gad.14.2.163 · Cited by 1,754
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability
Radisky, D. C., Levy, D. D., Littlepage, L. E., Liu, H., Nelson, C. M., Fata, J. E., Leake, D., Godden, E. L., Albertson, D. G., Angela Nieto, M., et al. (2005) · Nature · doi:10.1038/nature03688 · Cited by 1,284 · cited 1×
“initiates transmembrane signaling in neighboring MECs, as well as mediates E-cadherin cleavage and breast cancer progression [243, 247, 248].”
Erler, J. T., Bennewith, K. L., Cox, T. R., Lang, G., Bird, D., Koong, A., Le, Q.-T., & Giaccia, A. J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.11.012 · Cited by 1,231
Regulation of matrix biology by matrix metalloproteinases
Mott, J. D., & Werb, Z. (2004) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2004.07.010 · Cited by 1,104
MicroRNA-21 Targets the Tumor Suppressor Gene Tropomyosin 1 (TPM1)
Zhu, S., Si, M.-L., Wu, H., & Mo, Y.-Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611393200 · Cited by 1,090
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Zhu, S., Wu, H., Wu, F., Nie, D., Sheng, S., & Mo, Y.-Y. (2008) · Cell Research · doi:10.1038/cr.2008.24 · Cited by 1,051 · cited 1×
“initiation of EMT by downregulating the expression of tropomyosin, leading to enhanced breast cancer motility, invasion, and anchorage-independent growth [220, 221].”
Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.004 · Cited by 918
Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response
Ashcroft, G. S., Yang, X., Glick, A. B., Weinstein, M., Letterio, J. J., Mizel, D. E., Anzano, M., Greenwell-Wild, T., Wahl, S. M., Deng, C., et al. (1999) · Nature Cell Biology · doi:10.1038/12971 · Cited by 911 · cited 1×
“[118] and renal [119] epithelial cells; (b) reduced the EMT and migratory abilities of keratinocytes to TGF-β [120, 121];”
Regulation of the Polarity Protein Par6 by TGFß Receptors Controls Epithelial Cell Plasticity
Ozdamar, B., Bose, R., Barrios-Rodiles, M., Wang, H.-R., Zhang, Y., & Wrana, J. L. (2005) · Science · doi:10.1126/science.1105718 · Cited by 881
The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP–dependent activation of TGF-β1
Mu, D., Cambier, S., Fjellbirkeland, L., Baron, J. L., Munger, J. S., Kawakatsu, H., Sheppard, D., Broaddus, V. C., & Nishimura, S. L. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200109100 · Cited by 729
Ikenouchi, J., Matsuda, M., Furuse, M., & Tsukita, S. (2003) · Journal of Cell Science · doi:10.1242/jcs.00389 · Cited by 678
Bardeesy, N., Cheng, K.-H., Berger, J. H., Chu, G. C., Pahler, J., Olson, P., Hezel, A. F., Horner, J., Lauwers, G. Y., Hanahan, D., et al. (2006) · Genes & Development · doi:10.1101/gad.1478706 · Cited by 674 · cited 1×
“is mirrored by the activation of Smad4 in pancreatic cells undergoing EMT induced by TGF-β [122].”
Turley, E. A., Veiseh, M., Radisky, D. C., & Bissell, M. J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1089 · Cited by 253
TGF-β1–induced expression of human Mdm2 correlates with late-stage metastatic breast cancer
Araki, S., Eitel, J. A., Batuello, C. N., Bijangi-Vishehsaraei, K., Xie, X.-J., Danielpour, D., Pollok, K. E., Boothman, D. A., & Mayo, L. D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39194 · Cited by 133
Cited by
The epigenetics of epithelial-mesenchymal plasticity in cancer
Tam, W. L., & Weinberg, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3336 · Cited by 1,163
Syed, V. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25496 · Cited by 482
Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis
Shu, D. Y., & Lovicu, F. J. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.08.001 · Cited by 387
Cancer Invasion: Patterns and Mechanisms
Krakhmal, N. V., Zavyalova, M. V., Denisov, E. V., Vtorushin, S. V., & Perelmuter, V. M. (2015) · Acta Naturae · doi:10.32607/20758251-2015-7-2-17-28 · Cited by 374
Augoff, K., McCue, B., Plow, E. F., & Sossey-Alaoui, K. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-5 · Cited by 363
Metadata
- Authors
- Taylor, M. A., Parvani, J. G., & Schiemann, W. P.
- Venue
- Journal of Mammary Gland Biology and Neoplasia
- Published
- 2010-05-15
- Volume
- 15
- Issue
- 2
- Pages
- 169-190
- ISSN
- 1083-3021 (ISSN-L)
- 1573-7039
- OpenAlex
- W2094535521
- Cited by
- 231
- References
- 30
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.